Therefore, it may be less critical for cancer cells to use Bcl-2 for suppressing the activity of IP3R3, because this isoform is the least sensitive to IP3 and thus to ongoing B-cell receptor (BCR) signaling. This evidence concerns the gene BCR and cancer.